Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib plus definitive radiotherapy in unresectable stage III EGFR-uncommon mutation lung adenocarcinoma
ChiCTR2500114582Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114582.